Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells $320,678.98 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at approximately $5,110,952.38. The trade was a 5.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock traded down $0.06 during trading hours on Wednesday, reaching $42.00. 305,985 shares of the company’s stock were exchanged, compared to its average volume of 405,737. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $48.89. The company has a market cap of $2.02 billion, a P/E ratio of -20.79 and a beta of 0.98. The company’s 50 day moving average is $42.80 and its two-hundred day moving average is $40.60.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The business’s revenue was up 89.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.57) EPS. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Leerink Partners boosted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $57.10.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC grew its holdings in shares of Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock worth $39,000 after acquiring an additional 1,127 shares during the period. Amalgamated Bank boosted its position in Mirum Pharmaceuticals by 60.8% during the second quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares during the last quarter. ProShare Advisors LLC acquired a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth $213,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth about $215,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.